Feb. 08, 2011

Human Genome Sciences and GlaxoSmithKline Announce Publication Phase 3 Study Results for BENLYSTA®

February 08, 2011
ROCKVILLE, Maryland, and LONDON, UK – Human Genome Sciences, Inc. (Nasdaq: HGSI) and GlaxoSmithKline PLC (GSK) announced publication of the BLISS-52 study of BENLYSTA® (belimumab) in autoantibody-positive patients with active systemic lupus erythematosus (SLE) in The Lancet.

Read more from HGSI

Read the LFA's research summary of the study


Related Stories

General News | Nov. 16, 2011

New England Journal of Medicine Publishes Results of Study of CellCept® for Lupus Nephritis

The New England Journal of Medicine published results from a long-term study for the treatment of lupus nephritis.

General News | Mar. 09, 2011

LFA Applauds FDA Decision to Approve Benlysta for the Treatment of Lupus

The U.S. Food and Drug Administration (FDA) approved the drug, BENLYSTA®, for the treatment of lupus, an autoimmune disease.